Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Bulks Up Oncology Development With Avila Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.

You may also be interested in...



Avila/Clovis Partnership Moves To The Clinic

Avila and Clovis have selected a drug candidate to move into human testing.

Avila/Clovis Partnership Moves To The Clinic

Avila and Clovis have selected a drug candidate to move into human testing.

Zerhouni Moves Up At Sanofi-Aventis To President Of Global R&D

Former NIH director drafted by Viehbacher in early 2009 to be his science advisor replaces Cluzel as R&D chief.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel